Results and discussion
Release of the β-chemokines MIP-1α, MIP-1β and RANTES from HIV-1-specific CTL lines and clones (Table 1) was quantified by immunoassay and compared with lytic activity and interferon-γ (IFN-γ) production. In all assays, significant β-chemokine release required the appropriate peptide antigen bound to HLA class I; representative data are shown in Figure 1 . This extends earlier work which demonstrated antigen-specific release of other cytokines by CTLs [4] and supports studies that correlated suppression of virus replication, as determined by bioassay, with lytic activity [5, 6] .
Despite increasing evidence that CTLs control HIV-1 infection in vivo, the significance of naturally occurring mutations within HIV-1 epitopes that reduce or abolish CTL recognition [7] remains uncertain. Recent work has suggested that evasion of CTL recognition contributes to both viral persistence following infection and progression to AIDS [8] [9] [10] . We therefore assessed the effect of naturally occurring amino acid variation within epitopes, represented in the experiments by synthetic peptides, on β-chemokine release by CTLs and compared this with the effect on cytolysis. In the donor 868 HLA-A2-restricted CTL line specific for the epitope SLYNTVATL (single-letter amino acid code), peptide variants with impaired ability to sensitize targets for lysis also failed to stimulate maximal β-chemokine release from CTLs when compared with wild-type peptide ( Figure 2 ) [11] . Similar results were obtained for the 3F, 3L and 3F/5A peptide variants [11] with the HLA-A2-restricted SLYNTVATL-specific CTL clone from donor 003; the 6I variant [10] with the HLA-B27-restricted KRWIIMGLNK-specific CTL line from donor 868; the 3F/5A variant [11] with the HLA-A2-restricted SLYNTVATL-specific CTL clone from donor 868; and the 3C variant [12, 13] with the HLA-A2-restricted VIYQYMDDL-specific CTL clone from donor 868 (data not shown). The observation that β-chemokine production parallels cytolytic activity with both wild-type and variant epitopes over a range of peptide concentrations suggests that naturally occurring epitope mutation facilitates HIV-1 evasion of both lytic and suppressor functions of CTLs.
Individuals that are homozygous for a mutant allele of CCR5 in which a 32 base-pair deletion causes a frameshift resulting in a non-functional receptor have been shown to be resistant to HIV-1 infection despite repeated exposure [2] ; in addition, there is some evidence that HIV-1 seropositive heterozygotes progress more slowly to AIDS [2] . As cellular CCR5 expression levels correlate with infectability by macrophage-tropic HIV-1 [14] , receptor blockade by endogenous β-chemokines might inhibit the propagation of infection within infected individuals, thereby slowing disease progression. The capacity of β-chemokines to control HIV-1 infection in vivo remains unknown, however; inhibition of virus entry does not necessarily correlate with suppression of viral replication [15] . Furthermore, CCR5 (pg/ml)
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(pg/ml) Table 1 (data not shown). Autologous or HLA-matched B-lymphoblastoid cell lines (B-LCL) were used as targets in all assays. Targets were pulsed with 50 µM peptide, or mock-pulsed with medium alone, for 90 min and washed twice prior to assay. Lysis and cytokine release were determined at 4 h. Background production of cytokines by target cells was minimal. IFN-γ release is known to occur following TCR signalling and its measurement in these initial assays was included as a methodological control. A degree of cross-reactivity was observed with recombinant interleukin-2 in the RANTES immunoassay. Although free peptide was not present in these assays, a contribution to chemokine release from bystander lysis (that is, lysis of neighbouring CTLs in the absence of cognate recognition through the TCR) cannot be excluded [28] ; CTLs lysed with water (in the presence of broad spectrum protease inhibitors) prior to antigen exposure, however, did not release significant amounts of MIP-1α or MIP-1β, suggesting that simple cytoplasmic release from CTLs acting as targets in assay cultures does not account for the observed coupling of cytolytic activity with the release of these β-chemokines. RANTES (as determined by immunoassay) was detected in CTL lysates (data not shown). In time course experiments, MIP-1α, MIP-1β and IFN-γ production was detected only after a lag phase of approximately 90 min following antigen presentation, consistent with regulation at the level of transcription; RANTES release, in contrast, was observed within several minutes. These observations suggest that RANTES is released from a pre-formed store within the CTLs. Chemokine concentrations achieved by TCR triggering of CTLs generally ranked MIP-1β > MIP-1α/RANTES. Background release of β-chemokines (that is, release in the absence of peptide, or with an unrelated peptide) by CTLs was most significant for RANTES, and decreased with time from restimulation.
receptor blockade does not account fully for CD8 + lymphocyte-mediated inhibition of HIV-1 replication [2, 5, [16] [17] [18] [19] [20] .
As yet poorly characterized secreted or cell-associated factors with more potent suppressor activity may have a greater effect on disease progression [16] .
Chemokines play a central role in orchestrating host cellular defences through their pro-inflammatory, chemoattractant and cytomodulatory properties as well as inhibiting entry of HIV-1 into cells [21] [22] [23] [24] . Their release by virus-specific CTLs following the recognition of an infected host cell may be essential for the coordination of an effective antiviral immune response [23] . Subversion of these functions by antigenic variation could seriously impair antiviral immunity, and so provide a potent mechanism of immune evasion.
Materials and methods

Donors were either asymptomatic HIV-1-infected individuals from the Oxford Haemophilia Centre or genitourinary clinics in the Oxford
Brief Communication 357 Effects of natural epitope variants on cytolysis and β-chemokine production by the donor 868 HLA-A2-restricted SLYNTVATL-specific CTL line (12 days post-restimulation). An E:T ratio of 6:1 was used in each experiment. Lysis and β-chemokine release were measured at 6 h and are plotted against peptide concentration. Results are shown for the SLYNTVATL variants (a) 3F, (b) 3F/5A and (c) 3S and for the peptides AFHHVAREL (HLA-A2-restricted peptide epitope corresponding to amino acids 190-198 of Nef, included as a specificity control) and SLYNTVATL in (a-c). Background production of chemokines by the B-LCL targets in these assays was significant only for MIP-1α (510 pg/ml) and was subtracted from experimental values. These assays were performed in the presence of free peptide, conditions under which CTL-CTL lysis may be significant [28] . Some β-chemokine release may therefore be due to CTLs acting as targets in culture, either throughout the assay (RANTES), or following activation by antigen (MIP-1α and MIP-1β). Similar patterns were observed with targets prepulsed with peptide (concentration 1 µM) and with free peptide in the absence of targets (that is, with CTLs presenting antigen to each other). Release of β-chemokines also paralleled cytolysis with the 3C, 3L, 6I, 3F/6I, 6I/8V, 3F/8V and 3F/6I/8V peptide variants (data not shown); these variants have been shown to bind HLA-A2 [11] . Differences in the peptide sensitivity of these CTL responses might reflect varying thresholds of detection, but previous work has demonstrated that different CTL functions might be observed at different levels of TCR occupancy [29] .
region, or individuals with primary HIV-1 infection from the Chelsea and Westminster Hospital, London. HLA type was determined by amplification refractory mutation system (ARMS)-PCR with sequence-specific primers [25] . Peptides were synthesized using standard fluorenylmethoxycarbonyl (Fmoc) techniques and were >90% pure as determined by high-pressure liquid chromatography (Research Genetics). Peptide-specific CTL lines and clones were derived from donor peripheral blood mononuclear cells as described previously [26, 27] ; the specificities and origins of the CTLs used in this work are described in Table 1 . CTLs were washed twice in RPMI-1640 (Sigma) and diluted in fresh medium prior to assay. Cytolytic activity was determined using standard 51 Cr release methodology as described previously [27] . Supernatants were assayed for MIP-1α, MIP-1β, RANTES and IFN-γ with commercially available quantitative immunoassays (R&D Systems); standard calibration curves were constructed with each assay. All data points shown represent the mean of duplicate assays.
